Suppr超能文献

三磷酸鸟苷合成酶使克氏锥虫具有生长、生存优势,并对抗原生动物药物产生耐药性。

Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi.

机构信息

Instituto de Patología Experimental, Universidad Nacional de Salta - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Salta, Argentina.

Instituto de Agrobiotecnología del Litoral, Universidad Nacional del Litoral - CONICET, Santa Fe, Argentina.

出版信息

Free Radic Biol Med. 2019 Jan;130:23-34. doi: 10.1016/j.freeradbiomed.2018.10.436. Epub 2018 Oct 23.

Abstract

BACKGROUND

Chagas cardiomyopathy, caused by Trypanosoma cruzi infection, continues to be a neglected illness, and has a major impact on global health. The parasite undergoes several stages of morphological and biochemical changes during its life cycle, and utilizes an elaborated antioxidant network to overcome the oxidants barrier and establish infection in vector and mammalian hosts. Trypanothione synthetase (TryS) catalyzes the biosynthesis of glutathione-spermidine adduct trypanothione (T(SH)) that is the principal intracellular thiol-redox metabolite in trypanosomatids.

METHODS AND RESULTS

We utilized genetic overexpression (TryS) and pharmacological inhibition approaches to examine the role of TryS in T. cruzi proliferation, tolerance to oxidative stress and resistance to anti-protozoal drugs. Our data showed the expression and activity of TryS was increased in all morphological stages of TryS (vs. control) parasites. In comparison to controls, the TryS epimastigotes (insect stage) recorded shorter doubling time, and both epimastigotes and infective trypomastigotes of TryS exhibited 36-71% higher resistance to HO (50-1000 μM) and heavy metal (1-500 μM) toxicity. Treatment with TryS inhibitors (5-30 μM) abolished the proliferation and survival advantages against HO pressure in a dose-dependent manner in both TryS and control parasites. Further, epimastigote and trypomastigote forms of TryS (vs. control) T. cruzi tolerated higher doses of benznidazole and nifurtimox, the drugs currently administered for acute Chagas disease treatment.

CONCLUSIONS

TryS is essential for proliferation and survival of T. cruzi under normal and oxidant stress conditions, and provides an advantage to the parasite to develop resistance against currently used anti-trypanosomal drugs. TryS indispensability has been chemically validated with inhibitors that may be useful for drug combination therapy against Chagas disease.

摘要

背景

克氏锥虫感染引起的恰加斯心肌病仍然是一种被忽视的疾病,对全球健康有重大影响。寄生虫在其生命周期中经历了几个形态和生化变化的阶段,并利用一个精心设计的抗氧化网络来克服氧化剂屏障,并在媒介和哺乳动物宿主中建立感染。硫醇合成酶(TryS)催化谷胱甘肽-亚精胺加合物硫醇(T(SH))的生物合成,该化合物是原生动物中的主要细胞内硫醇-氧化还原代谢物。

方法和结果

我们利用遗传过表达(TryS)和药理学抑制方法来研究 TryS 在 T. cruzi 增殖、对氧化应激的耐受和对抗原生动物药物的抗性中的作用。我们的数据表明,TryS 在 TryS(与对照相比)寄生虫的所有形态阶段的表达和活性都增加了。与对照相比,TryS 无鞭毛体(昆虫阶段)记录的倍增时间更短,TryS 的无鞭毛体和感染性锥鞭毛体对 HO(50-1000 μM)和重金属(1-500 μM)毒性的抗性分别提高了 36-71%。TryS 抑制剂(5-30 μM)以剂量依赖性方式处理 TryS 和对照寄生虫,均可消除对 HO 压力的增殖和生存优势。此外,TryS(与对照相比)T. cruzi 的无鞭毛体和锥鞭毛体形式耐受更高剂量的苯并咪唑和硝呋替莫,这两种药物目前用于急性恰加斯病的治疗。

结论

TryS 对 T. cruzi 在正常和氧化应激条件下的增殖和存活是必不可少的,并为寄生虫提供了对目前用于抗原生动物药物产生抗性的优势。TryS 的不可或缺性已通过抑制剂进行了化学验证,这些抑制剂可能对针对恰加斯病的联合药物治疗有用。

相似文献

4
Trypanothione biosynthesis in Leishmania major.硕大利什曼原虫中的锥虫硫醇生物合成
Mol Biochem Parasitol. 2005 Jan;139(1):107-16. doi: 10.1016/j.molbiopara.2004.10.004.

引用本文的文献

5
Targeting Trypanothione Metabolism in Trypanosomatids.靶向原虫的硫醇代谢。
Molecules. 2024 May 9;29(10):2214. doi: 10.3390/molecules29102214.

本文引用的文献

2
Life and death of Trypanosoma cruzi in presence of metals.金属存在下克氏锥虫的生与死。
Biometals. 2017 Dec;30(6):955-974. doi: 10.1007/s10534-017-0064-4. Epub 2017 Oct 28.
7
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.随机试验用苯硝唑治疗慢性恰加斯心肌病。
N Engl J Med. 2015 Oct;373(14):1295-306. doi: 10.1056/NEJMoa1507574. Epub 2015 Sep 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验